---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-26-000003"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:32:11.149524+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26

## Summary
- Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.
- Estimated impact of $1.26 per diluted share on both GAAP and non-GAAP EPS.
- Expense line item newly presented separately since Q1 2025.
- Final Q4 2025 results not finalized; subject to closing procedures.
- Company does not forecast such expenses due to uncertainty in timing and magnitude.

## SEC filing metadata
- accession: 0000875045-26-000003
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504526000003/0000875045-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504526000003/biib-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-26-000003
- JSON: https://secwatch.observer/filing/0000875045-26-000003.json
- Plain text: https://secwatch.observer/filing/0000875045-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.